The ESHRE 2022 Endometriosis Guideline recommends empirical medical treatment for suspected endometriosis in women with chronic pelvic pain before diagnostic laparoscopy. Which medical treatment is specifically NOT recommended as first-line empirical therapy because it lacks evidence for suppressing endometriosis-associated pain?

• A Combined oral contraceptive pill (COCP)
• B Danazol ✓
• C Progestogens (dienogest, medroxyprogesterone acetate)
• D NSAIDs alone as monotherapy for dysmenorrhoea in endometriosis

Explanation

Danazol (a synthetic androgen/progestogen) was historically used for endometriosis but is no longer recommended as first-line empirical therapy due to its significant androgenic side effects (acne, hirsutism, voice changes, weight gain), hepatotoxicity, and unfavourable risk-benefit profile compared to modern options. ESHRE 2022 recommends COCP, progestogens (dienogest is the most evidence-based), and LNG-IUS as first-line empirical treatments. GnRH analogues are second-line. NSAIDs are recommended for pain relief (analgesic effect) but not as sole disease-modifying treatment.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.